Vaxcyte Jumps on Phase 3 Vaccine Win as Biotech Stocks Set Records
Vaxcyte shares shot up 31 percent after strong Phase 3 results for its pneumococcal vaccine. The news sparked a rally, sending several biotech stocks to fresh 52-week highs.
Biotech Catalysts 1 article
Biotech Catalysts tracks discrete events that can materially change the evidence or expectations surrounding a biotechnology company. Trial readouts, regulatory decisions, pipeline milestones and launches are examined for what is known beforehand, what uncertainty remains and how outcomes alter development value. The category is event-focused rather than a general market calendar: a catalyst qualifies when it is tied to a scientific, clinical, regulatory or commercial inflection point in biotechnology.